InvestorsHub Logo
Followers 155
Posts 2642
Boards Moderated 0
Alias Born 01/29/2004

Re: Steady_T post# 407764

Saturday, 03/18/2023 9:15:27 PM

Saturday, March 18, 2023 9:15:27 PM

Post# of 462171
Exactly. Anavex science threatens so many.

...the scientific publishing industry is quite hostile to new theories that go against the mainstream zeitgeist. Anavex clearly falls into that category.

Anavex may well be having a difficult time finding a publisher willing to publish a paper on an approach that is not just outside the mainstream but is a theory that will change the paradigm and impact a lot of careers.


"Zeitgeist" is German, meaning "spirit of the time." And for how long has it been understood, perceived, and preached that amyloid wastes in neurons are THE CAUSE of Alzheimer's? How many professional careers rest entirely on this premise? Who and what might be jeopardized if incontrovertible evidence can be presented showing that, in fact, the root causes of Alzheimer's, in all of its forms, are from a dysfunction in the sigma-1 receptor?

We can see a bit this on this message board. How many posts over the years loudly claimed that "Alzheimer's is a tricky disease, and no one can really know what causes it?" The implication, of course, is that Anavex can't possibly have the answer.

So, yes, there may well be some entrenched parties who will desire to hold and preserve the amyloid thesis for Alzheimer's. Entire careers and billions of dollars of research have been focused on the amyloid thesis --- for so long that it can't possibly be wrong. How could some tiny biotech startup think that it could effectively challenge and negate the universally-accepted amyloid zeitgeist? The really smart people, including many who post here, know better.

Consequently, as Dr. Missling knows, the evidence for Anavex drug MOAs (mechanisms of action) must be incontrovertible; so much so that any reviewer of the evidence will be forced, ever so hesitantly, to accept it; fearing for his reputation when the evidence becomes public. The reviewer of an Anavex paper submitted for publication in a respected journal will realize that he won't be the only reader of the evidence. If he rejects the evidence and the paper, he will be open to close scrutiny and public criticism when the broader scientific community reads the evidence.

When the time is right, Missling will release his data to multiple outlets and venues. It will be read by not just two or three "peers" at some medical journal. The data will also be posted online, for the entire world to ponder. Eventually, the profound facts and realities of Anavex science will prevail. It will be interesting to see how Dr. Missling will arrange this. Quietly, behind the scenes, he's working it all out; along with his new hires. Time won't be the tell. It will be the new evidence quietly being discovered right now.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News